ArticleFrontiers in immunology2024
Case report: Cancer-free survival after chemotherapy, targeted immunotherapy combination with proton therapy following space making technique in a patient with cholangiocarcinoma after choledochal cyst resection.
Article in Frontiers in immunology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Global research trends in surgical management of choledochal cysts: a bibliometric analysis from 2000 to 2024.Frontiers in medicine · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Choledochal cysts (CCs) are rare cystic dilations of the intrahepatic and/or extrahepatic bile ducts. Malignancies arising during follow-up after excision of CCs have been reported in both children and adults, with no typical time frame for malignancy development. We present a case of a patient diagnosed with CCs 36 years ago, who underwent resection and subsequently developed cancer. The patient received chemotherapy, targeted therapy, and immunotherapy, with efficacy evaluation indicating a state of stable disease. Considering tumor resistance after continuous systemic therapy and an unresectable tumor, proton therapy was selected for the next treatment. To prevent gastrointestinal side effects after proton therapy, the bile-enteric anastomosis was dismantled, and a greater omentum strip was used to fill the subhepatic space, creating a barrier between the biliary duct and the intestine. The patient successfully underwent proton therapy without any gastrointestinal complications. As CC-associated malignancy poses a lifelong risk even with complete resection, surveillance should be maintained throughout the follow-up period. Comprehensive treatment should be adopted to improve prognosis in malignancy after CC resection.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.